A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-08 and is reviewed periodically as new material appears.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Nanoparticles are classified as having at least one of its dimensions in the range of 1-100 nanometers (nm). The small size of nanoparticles allows them to have unique characteristics which may not be possible on the macro-scale. Self-assembly is the spontaneous organization of smaller subunits to form larger, well-organized patterns. For nanoparticles, this spontaneous assembly is a consequence of interactions between the particles aimed at achieving a thermodynamic equilibrium and reducing the system's free energy. The thermodynamics definition of self-assembly was introduced by Professor Nicholas A. Kotov. He describes self-assembly as a process where components of the system acquire non-random spatial distribution with respect to each other and the boundaries of the system. This definition allows one to account for mass and energy fluxes taking place in the self-assembly processes. This process occurs at all size scales, in the form of either static or dynamic self-assembly. Static self-assembly utilizes interactions amongst the nano-particles to achieve a free-energy minimum. In solutions, it is an outcome of random motion of particles and the affinity of their binding sites for one another. A dynamic system is forced to not reach equilibrium by supplying the system with a continuous, external source of energy to balance attractive and repulsive forces. Magnetic fields, electric fields, ultrasound fields, light fields, etc. have all been used as external energy sources to program robot swarms at small scales.
A repository version of H.P. Acthar gel was approved in 2010 and as of January 2017 was also under the control of Mallinkrodt. Synthetic forms were created as a replacement for the animal-derived products. In the US, available forms of tetracosactide/cosyntropin, the synthetic form of corticotrophin, have been approved only for diagnostic uses, and have included:
== As a drug target == The oxoglutarate dehydrogenase complex (α-ketoglutarate dehydrogenase complex) is responsible for converting AKG into succinyl-CoA in the citric acid cycle. It is one of the rate-limiting enzymes in the cycle. In breast cancer with lung metasatsis models, inhibiting this enzyme (causing an accumulation of AKG) reduces cancer cell growth; a similar effect is observed with AKG supplementation in mice with B-cell lymphoma. On the other hand, a dysfunction of this enzyme (again causing AKG accumulation) leads to increased lipid peroxidation in CHCHD2-linked Parkinson's disease models and appears to be partly responsible for elevated phosphorylated α-synuclein levels, as improving the function of this complex causes both AKG and phosphorylated α-synuclei to decrease.
1993/3229) Milk Marketing Board Scheme of Reorganisation (Extension of Period for Application) Order 1993 (S.I. 1993/3230) Merchant Shipping (Musters and Training) (Amendment) Regulations 1993 (S.I. 1993/3231) Merchant Shipping (Pilot Ladders and Hoists) (Amendment) Regulations 1993 (S.I. 1993/3232) Dairy Produce Quotas (Amendment) Regulations 1993 (S.I. 1993/3234) Pensions Increase (Approved Schemes) (National Health Service) (Scotland) Amendment Regulations 1993 (S.I. 1993/3235) Council Tax (Transitional Reduction Scheme) (Scotland) (No.2) Regulations 1993 (S.I. 1993/3236) Railways Act 1993 (Commencement No. 1) Order 1993 (S.I. 1993/3237) Road Traffic Act 1991 (Commencement No. 9 and Transitional Provisions) Order 1993 (S.I. 1993/3238) Road Traffic (Special Parking Areas) (London Boroughs of Richmond upon Thames and Southwark) Order 1993 (S.I. 1993/3239) Act of Sederunt (Sheriff Court Summary Application Rules) 1993 (S.I. 1993/3240) Insurance Accounts Directive (Miscellaneous Insurance Undertakings) Regulations 1993 (S.I. 1993/3245) Companies Act 1985 (Insurance Companies Accounts) Regulations 1993 (S.I. 1993/3246) Animals and Animal Products (Import and Export) Regulations 1993 (S.I. 1993/3247) Artificial Breeding of Sheep and Goats Regulations 1993 (S.I. 1993/3248) Importation of Bees (Amendment) Order 1993 (S.I. 1993/3249) Specified Animal Pathogens Order 1993 (S.I. 1993/3250) Parliamentary Pensions (Additional Voluntary Contributions Scheme) Regulations 1993 (S.I. 1993/3252) Parliamentary Pensions (Consolidation and Amendment) Regulations 1993 (S.I.
Sources: en.wikipedia.org
Z-DNA binding protein 1, also known as Zuotin, is a Saccharomyces cerevisiae yeast gene. Zuo1 has been identified in vitro as a tRNA and Z-DNA binding protein. The name "zuotin" is derived from the Chinese word "zuo" meaning "left". It is a member of Hsp40 family. Like all other Hsp40 members it also contains a classic J domain. In 1990, Shuguang Zhang of MIT made a serendipitous discovery of a self-assembling peptide in yeast protein Zuotin. This discovery led to the development of a new field of peptide nanobiotechnology and to designs of a variety of self-assembling peptides for widespread uses, including peptide hydrogels in materials science, 3D tissue cell culture and tissue engineering, nanomedicine, sustained molecular releases, clinical and surgical applications. Zuotin and related proteins contain a unique Zuotin homology domain (ZHD). It associates with the Hsp70 family Ssz1 to form a ribosome associated complex (RAC). In such a complex, the N-terminal domains (including the J domain) associates with Ssz1p on the surface of the large (60S) ribosomal subunit. ZHD provides further contacts with the 60S subunit and connects to a subunit-spanning medium domain (MD), the "neck" of RAC. The four-helix-bundle RAC head domain is located at the C-terminus and binds the small (40S) subunit. The J domain-Ssz1p complex, located over the peptide exit tunnel of the large ribosomal subunit, helps the nascent peptide fold.
The expiry of the Malaysian New Economic Policy (NEP) in 1990 allowed Mahathir to outline his economic vision for Malaysia. In 1991, he announced Vision 2020, under which Malaysia would aim to become a fully developed country within 30 years. The target would require average economic growth of approximately seven per cent of gross domestic product per annum. One of Vision 2020's features would be to gradually break down ethnic barriers. Vision 2020 was accompanied by the NEP's replacement, the National Development Policy (NDP), under which some government programmes designed to benefit the bumiputera exclusively were opened up to other ethnicities. Mahathir highlighted that the policy would balance growth with addressing economic imbalances across regions and society. The NDP achieved one of its main aims — poverty reduction. By 1995, less than nine per cent of Malaysians lived in poverty, and income inequality had narrowed. Mahathir also introduced the Bangsa Malaysia policy, which aimed to facilitate greater representation of non-Malay ethnicities in Malaysia. Additionally, he popularised slogans like Malaysia Boleh (Malaysia Can) in his domestic politics. Mahathir's government cut corporate taxes and liberalised financial regulations to attract foreign investment. The economy grew by over nine per cent per annum until 1998, prompting other developing countries to emulate Mahathir's policies. Mahathir's bold economic initiatives propelled Malaysia to become the 17th largest trading nation globally.
In addition to pure indica, sativa, and ruderalis varieties, hybrid varieties with varying ratios of these three types are common, such as the White Widow hybrid which has about 60% indica and 40% sativa ancestry. These hybrid varieties exhibit traits from both parental types. There are also commercial crossbred hybrids which contain a mix of both ruderalis, indica or sativa genes, and are usually autoflowering varieties. "Lowryder" was an early auto-flowering hybrid that retained the flowering behavior of ruderalis plants, while also producing appreciable amounts of THC and CBD. Autoflowering cannabis varieties have the advantage of being discreet due to their small stature. They also require shorter growing periods, as well as having the additional advantage that they do not rely on a change in the photoperiod to determine when to flower. Breeding requires pollinating a female cannabis plant with male pollen. Although this occurs spontaneously and ubiquitously in nature, the intentional creation of new varieties typically involves selective breeding in a controlled environment.
=== Myopathies with central nuclei === Myopathies with central nuclei, such as myotubular myopathy, involves an error in the gene involved in vesicle movement throughout the cell. This creates problems in vesicles reaching the plasma membrane with the cellular components necessary to fuse myoblast, a major step in the formation of the skeletal muscle. This creates structural problems throughout the skeletal muscle and in the Z line of the sarcomere, creating the weakness in the muscle.
1993/2755) Housing (Right to Buy) (Priority of Charges) (No. 2) Order 1993 (S.I. 1993/2757) Mortgage Indemnities (Recognised Bodies) (No.2) Order 1993 (S.I. 1993/2758) Food Labelling (Amendment) Regulations 1993 (S.I. 1993/2759) Rules of the Supreme Court (Amendment No. 2) 1993 (S.I. 1993/2760) Northern Ireland (Emergency Provisions) Act 1991 (Codes of Practice) (No. 1) Order 1993 (S.I. 1993/2761) Leasehold Reform, Housing and Urban Development Act 1993 (Commencement and Transitional Provisions No. 3) Order 1993 (S.I. 1993/2762) Environmentally Sensitive Areas (Central Borders) Designation Order 1993 (S.I. 1993/2767) Environmentally Sensitive Areas (Stewartry) Designation Order 1993 (S.I. 1993/2768) Charities (Designated Religious Bodies) (Scotland) Order 1993 (S.I. 1993/2774) Plant Breeders' Rights (Amendment) Regulations 1993 (S.I. 1993/2775) Plant Breeders' Rights (Trees, Shrubs and Woody Climbers) Scheme 1993 (S.I. 1993/2776) Plant Breeders' Rights (Tomatoes) Scheme 1993 (S.I. 1993/2777) Plant Breeders' Rights (Miscellaneous Ornamental Plants) (Variation) Scheme 1993 (S.I. 1993/2778) Plant Breeders' Rights (Sainfoin and Birdsfoot Trefoil) Scheme 1993 (S.I. 1993/2779) Plant Breeders' Rights (Herbaceous Perennials) (Variation) Scheme 1993 (S.I. 1993/2780) Plant Breeders' Rights (Quince Rootstocks) Scheme 1993 (S.I. 1993/2781) Finance Act 1993 (Appointed Day No. 2) Order 1993 (S.I. 1993/2782) Local Government Superannuation (South Yorkshire Transport Limited) Regulations 1993 (S.I. 1993/2783) Northern Ireland (Emergency Provisions) Act 1991 (Codes of Practice) (No.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.